Disease · MONDO_0005252
Comparisons in its trials263
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 263
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
| Omecamtiv Mecarbil vs Placebo: deaths from any cause | 1,078 of 4,120 | 1,078 of 4,112 | 8,232 | NCT02929329 | Trial comparisons |
| Omecamtiv Mecarbil vs Placebo: serious adverse events | 2,373 of 4,110 | 2,435 of 4,101 | 8,211 | NCT02929329 | Trial comparisons |
| Nesiritide vs Placebo: Number of Patients With Renal Impairment | 1,032 of 3,498 | 968 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 30 | 126 of 3,498 | 141 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 180 | 429 of 3,498 | 447 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: serious adverse events | 5 of 3,498 | 2 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Persistent or Worsening Heart Failure and All-Cause Mortality | 147 of 3,459 | 165 of 3,462 | 6,921 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality | 372 of 3,423 | 402 of 3,415 | 6,838 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality | 321 of 3,423 | 345 of 3,413 | 6,836 | NCT00475852 | Trial comparisons |
| Serelaxin (RLX030) vs Placebo: deaths from any cause | 363 of 3,257 | 386 of 3,248 | 6,505 | NCT01870778 | Trial comparisons |
| Serelaxin (RLX030) vs Placebo: serious adverse events | 412 of 3,257 | 424 of 3,248 | 6,505 | NCT01870778 | Trial comparisons |
| Ivabradine vs Placebo: Hospitalisation for Worsening Heart Failure | 514 of 3,241 | 672 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. | 793 of 3,241 | 937 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Unplanned Hospitalisation for CV Reason | 909 of 3,241 | 1,047 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Death From Heart Failure | 113 of 3,241 | 151 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Hospitalisation for Cardiovascular Reason | 977 of 3,241 | 1,122 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Hospitalisation for Any Cause | 1,231 of 3,241 | 1,356 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Secondary Composite Endpoint | 825 of 3,241 | 979 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
| Ivabradine vs Placebo: Cardiovascular Death | 449 of 3,241 | 491 of 3,264 | 6,505 | NCT02441218 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005252/comparisons